---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-002010"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2026-01-14T23:59:59+00:00"
generated_at: "2026-05-16T10:25:14.443076+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics outlines milestones through 2028; cemsidomide Phase 2 trial on track for Q1 2026

## Summary
- Cemsidomide Phase 2 MOMENTUM trial to begin Q1 2026; recommended Phase 2 dose 100 µg.
- Phase 1b combination with elranatamab to start Q2 2026; potential accelerated approval path for 4L+ by end 2028.
- Phase 1 data: 40% ORR at 75 µg, 53% ORR at 100 µg in heavily pretreated multiple myeloma patients.
- Cash runway to end 2028 provides funding through key value inflection points including NDA submission.
- Internal discovery strategy targeting inflammation and neurodegeneration; up to 3 IND applications by end 2028.

## SEC filing metadata
- accession: 0001628280-26-002010
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2026-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828026002010/0001628280-26-002010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828026002010/cccc-20260114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-002010
- JSON: https://secwatch.observer/filing/0001628280-26-002010.json
- Plain text: https://secwatch.observer/filing/0001628280-26-002010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.